No later than July 1, 2020, and every two (2) years thereafter, the department shall report to the senate and house of representatives health and welfare committees on:
(1) The activities and outcomes of syringe and needle exchange programs operating in the state, including: The number of individuals who have exchanged syringes or needles;
(2) The number of used syringes or needles exchanged for new syringes or needles;
(3) The number of new syringes or needles provided in exchange for used syringes or needles;
(4) The estimated impact, if any, that the programs have had on blood-borne infection rates; and
(5) The estimated impact, if any, of the programs on the number of individuals receiving treatment for a substance use disorder;
(6) The potential for additional reductions in the number of syringes and needles contaminated with blood-borne disease if the programs receive additional funding;
(7) The potential for additional reductions in state and local government spending if the programs receive additional funding;
(8) Whether the programs promote illicit use of drugs; and
(9) Whether the programs, in the opinion of the director, should be continued, continued with modifications, or terminated.